Alembic Pharmaceuticals has informed that its Associate Company, Rhizen Pharmaceuticals SA (Rhizen) has issued a Press Release announcing that it has received approval of its lnvestigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company has enclosed Rhizen's press release tilted ‘Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020’. Alembic Pharmaceuticals through its wholly owned subsidiary holds 50% ownership in Rhizen.
The above information is a part of company’s filings submitted to BSE.
